Biodesix, Inc., a fully integrated molecular diagnostics company advancing products for personalized medicine, today announced that the U.S. Patent & Trademark Office (PTO) has issued four patents which collectively provide broad intellectual property protection for the Company’s products and technology. The patents provide additional coverage in multiple tumor types for the Company’s first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer.
Specifically, the patents cover the selection of non-small cell lung cancer (NSCLC) patients for treatment with antibodies directed against the epidermal growth-factor receptor (EGFR) pathway (patent number 7,858,389); the selection of colorectal cancer patients for treatment with drugs targeting the EGFR pathway (7,858,390); the selection of head and neck cancer patients for treatment with drugs targeting the EGFR pathway (7,867,775); and the Company’s laboratory operations: a method and system for determining whether a drug will be effective on a patient with a disease (7,879,620), a continuation of the company’s foundational ‘905 patent awarded in June 2010.
Drug therapies directed against the epidermal growth factor pathway and related molecular targets play an increasingly important role in cancer therapy and represent the majority of oncology therapies in development, but do not provide benefit for all patients.
“The issuance of these patents recognizes our approach and innovation in delivering rapid turnaround, serum-based tests to the oncology community as unique,” commented David Brunel, Biodesix CEO. “Our latest patents enhance the overall commercial profile of VeriStrat and strengthen our IP portfolio in molecular diagnostics.”
Biodesix is a fully integrated molecular diagnostics company advancing the development of products for personalized medicine. Biodesix provides physicians with tools for earlier disease detection, more accurate diagnosis, and better therapeutic guidance. In 2009, Biodesix launched VeriStrat®, a serum proteomic test that helps physicians guide treatment for patients with non-small cell lung cancer. VeriStrat is based on ProTS®, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patient’s condition or likely outcome in response to therapy. The ProTS® platform has broad application and provides the foundation for collaborations with leading researchers as well as partnerships with biotechnology and pharmaceutical companies seeking to develop companion diagnostics and improve the targeting of their therapies. For more information about Biodesix, please visit the Company’s website at www.Biodesix.com